Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310858 | 0.93 | MAPK14 (0.80) | MAPK14 | |
| SCHEMBL1311225 | 0.88 | MAPK14 (1.00) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1312162 | 0.87 | MAPK14 (0.77) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1311191 | 0.87 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL1311301 | 0.85 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL1311772 | 0.85 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL1310604 | 0.85 | MAPK14 (1.00) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL9104892 | 0.84 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL1311100 | 0.83 | MAPK14 (0.72) | MAPK14 | |
| SCHEMBL1312373 | 0.83 | MAPK14 (0.79) | MAPK14LCKKITKDRMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2334674-B1 | Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. | AMGEN INC (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2010025201-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | MAPK1, MAP3K1, MAP4K2 | MAPK14 46/4885LCK 255/4885KIT 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.